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The B subunit of the subtilase cytotoxin (SubB) recognises N-glycolylneuraminic acid (Neu5Gc) con-
taining glycans, the most prominent form of aberrant glycosylation in human cancers. We have previ-
ously engineered SubB by construction of a SubBDS106/DT107 mutant (SubB2M) for greater speciﬁcity and
enhanced recognition of Neu5Gc containing glycans. In this study, we further explore the utility of
SubB2M as a Neu5Gc lectin by showing its improved speciﬁcity and recognition for Neu5Gc containing
glycans over the wild-type SubB protein and an anti-Neu5Gc IgY antibody in a N-acetylneuraminic acid
(Neu5Ac)/Neu5Gc glycan array and by surface plasmon resonance. Far-western blot analysis showed that
SubB2M preferentially binds to bovine serum glycoproteins over human serum glycoproteins. SubB2M
was also able to detect Neu5Gc containing bovine glycoproteins spiked into normal human serum with
greater sensitivity than the wild-type SubB and the anti-Neu5Gc IgY antibody. These results suggest that
SubB2M will be a useful tool for the testing of serum and other bodily ﬂuids for cancer diagnosis and
prognosis.
© 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Shiga toxigenic Escherichia coli (STEC) Subtilase cytotoxin
(SubAB) targets a2-3-linked N-glycolylneuraminic acid (Neu5Gc)
via its pentameric B-subunit SubB [1,2]. Neu5Gc terminating gly-
cans are not expressed at signiﬁcant levels on healthy human tis-
sues [3e6] as humans produce an inactive cytidine
monophosphate N-acetylneuraminic acid hydroxylase (CMAH)
enzyme [7]. However, Neu5Gc containing glycans are the most
prominent form of aberrant glycosylation in human cancers and
can be explained by dietary intake of red meat and dairy products
leading to the absorption of Neu5Gc [8].
In recent work we engineered the SubB protein to increase
speciﬁcity and selectivity for Neu5Gc containing glycans by limiting
Neu5Ac recognition and by broadening the types of Neu5Gc linkages
recognised [9]. Of the six mutant SubB proteins produced, the
SubBDS106/DT107 mutant (SubB2M) fulﬁlled the aim of less Neu5Acm.jennings@grifﬁth.edu.au (M.P. Je
r Inc. This is an open access articlerecognition and broadened Neu5Gc linkage recognition [9],
including binding to Neu5Gca2-6 containing glycans, possible cancer
antigens [10]. The improved SubB2M lectin offers a potential new
tool for the testing of serum and other bodily ﬂuids from individuals
with or suspected of having cancer. To further conﬁrm the suitability
of SubB2M as a tool for Neu5Gc detection in both laboratory and
diagnostic settings we tested the protein with a new Neu5Ac/
Neu5Gc paired structure glycan array and used the lectin in immu-
noassays, including, far-western blots and in Surface Plasmon
Resonance (SPR) to detect Neu5Gc containing glycoproteins.
2. Materials and methods
2.1. Expression and puriﬁcation of wild-type SubB and SubB2M
The wild-type SubB and SubB2M recombinant proteins were
expressed and puriﬁed as previously described [9].nnings).
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Neu5Ac/Neu5Gc glycan array slides were purchased from Z-
Biotech (Aurora, Colorado, USA). The arrays were performed as per
the manufacturer's instructions with the following modiﬁcations.
For each subarray 2 mg of SubB proteins were pre-complexed with
anti-His tag antibody (Cell signalling) and Alexa555 secondary and
tertiary antibodies (rabbit anti-mouse; goat anti-rabbit; Thermo
Scientiﬁc) at a ratio of 2:1:0.5:0.25 in a ﬁnal volume of 100 mL. This
100 ml antibody protein complex was added to the silicon gene
frame (Z-Biotech) without a coverslip. Washing was performed as
previously described [11] and scanned using an Innoscan 1100AL
scanner and analysed usingMapix analysis software as described in
Day et al. 2017 [12].
2.3. Surface plasmon resonance of SubB with Neu5Ac/Neu5Gc
glycan pairs
Surface plasmon resonance (SPR) was run using the Biacore
T200 system (GE) as described previously [9]. Brieﬂy, SubB,
SubB2M and anti-Neu5Gc IgY (Biolegend) were immobilized onto
ﬂow cell 2e4 of a series S sensor chip CM5 (GE) using the NHS
capture kit and ﬂow cell 1 was run as a blank immobilization.
Neu5Ac/Neu5Gc pairs were purchased from Chemily Glycoscience
(Atlanta, GA). Glycans were used across a ﬁve-fold dilution series at
a maximum concentration of 20 mM. Analysis was run using single
cycle analysis and double reference subtraction on the Biacore T200
evaluation software.
2.4. Far-western blot analysis
2.4.1. Glycoproteins
Each glycoprotein was diluted to 5mg/ml and treated with 20 U
of a2-3,6,8,9 neuraminidase (sialidase) A (New England BioLabs) in
a ﬁnal volume of 50 ml of 1GlycoBuffer 1 (New England BioLabs).
10 mg of human and bovine a1-acid glycoproteins (AGP), fetuin and
asialofetuin (Sigma-Aldrich) and native bovine MUC-1 (Creative
Bio-labs) (either with or without neuraminidase treatment) were
combined with 1X NuPAGE sample buffer and 5% (v/v) b-mercap-
toethanol, heated at 99 C for 10mins and loaded into an SDS-
polyacrylamide gel (NuPage 4e12% Bis-Tris gel, Invitrogen). The
separated proteins were then transferred to nitrocellulose mem-
brane for far-western blot analysis. The membranes were blocked
with 1% ﬁsh gelatin (Sigma-Aldrich) in phosphate buffered saline
(PBS) for 1 h and then washed once with PBS/0.05% Tween-20
(PBST). Then 1 mg/ml of wild-type SubB or SubB2M or chicken
anti-Neu5Gc IgY antibody (1:10 000) (BioLegend) was used to
detect Neu5Gc on glycoproteins. All membranes were washed in
1 PBST three times. Blots were probed with monoclonal anti-
polyhistidine-Alkaline Phosphatase mouse antibody (1:10 000)
(Sigma-Aldrich) to detect binding of SubB and SubB2M or with
rabbit anti-chicken IgY antibody (1:10 000) (Sigma-Aldrich) to
detect binding of the anti-Neu5Gc antibody, both diluted in PBS.
The membranes were washed with PBST three times, then devel-
oped with NBT/BCIP solution (Sigma-Aldrich) for 10min.
2.4.2. Sera from human and bovine
Serum samples were purchased from commercial suppliers:
human (Sigma-Aldrich) and bovine (Sigma-Aldrich). Serum sam-
ples were diluted to 5mg/ml and treated with 20 U of a2-3,6,8,9
neuraminidase (sialidase) A in a ﬁnal volume of 50 ml of 1Gly-
coBuffer 1. Samples were then incubated at 37 C for 2 h, as previ-
ously described [13]. 10 mg of total serum protein (either with or
without neuraminidase treatment) was combined with 1X NuPAGE
sample buffer and 5% (v/v) b-mercaptoethanol, heated at 99 C for10mins and loaded into an SDS-polyacrylamide gel. The separated
serum proteins were then transferred to nitrocellulose membrane
for far-western analysis. Membranes were probed with SubB,
SubB2M and anti-Neu5Gc antibody and detected as described
above for glycoproteins. Membranes were also probed with 1 mg/ml
of Sambucus nigra agglutinin (SNA)-1-alkaline phosphatase conju-
gate (EY Laboratories) in PBS to detect sialic acids on glyco-
conjugates as an additional positive control.
2.5. Surface plasmon resonance of SubB proteins with Neu5Gc
spiked human serum
Surface plasmon resonance (SPR) was run using the Biacore
S200 system (GE) as described previously [14]. Brieﬂy, SubB,
SubB2M and anti-Neu5Gc IgY were immobilized onto ﬂow cell 2e4
of a series S sensor chip CM5 (GE) using the NHS capture kit and
ﬂow cell 1 was run as a blank immobilization. Bovine a1-Acid
glycoprotein and MUC1 were spiked into 1% normal human
serum (NHS; Sigma-Aldrich) starting at 1mM. The protein was
diluted 1:2 in 1% NHS across 5e6 dilutions and 1% NHS was used as
the zero concentration control. Analysis was run using multi-cycle
analysis and double reference subtraction on the Biacore S200
evaluation software.
3. Results
3.1. Glycan array and SPR analysis of wild-type SubB and SubB2M
To further assess the speciﬁcity of SubB2M for Neu5Gc and
underlying glycan linkages, a Neu5Ac/Gc array from Z-Biotech was
employed. The Z-Biotech array features 40 Neu5Ac/Gc pairs and
one with both Neu5Ac and Neu5Gc on the one glycan, counted as
Neu5Gc for analysis, with both linear and branched structures
(Fig. S1). Binding to Neu5Gc structures was preferred by the wild-
type SubB, but there were four out of 40 Neu5Ac glycans that
were boundwith greater than 5000 relative ﬂuorescent units (RFU)
above background and 14 out of 41 Neu5Gc structures that had
binding below 5000 RFU (Fig. 1A and B). The SubB2M protein,
however, showed no binding to Neu5Ac glycans with greater than
5000 RFU above background and only ﬁve out of 41 Neu5Gc
structures had binding below 5000 RFU. Only eight of 40 Neu5Ac
glycans showed any binding above background for SubB2M (Fig. 1A
and C). It was also noted that SubB2M was better able to recognise
fucosylated Neu5Gc containing glycans, sialyl-Lewis A and X, with
improved binding to structures 3, 6, 9, 14, 17, 20, 23, 29 and 35
(Fig. 1B and C, Fig. S1). These are all structures containing Neu5Gc
only present on the same terminal end as the sub-terminal
fucosylation.
SPR analysis was performed on three sets of Neu5Ac/Gc pairs;
a2-3Neu5Ac/Gc Lacto-N-neotetraose (Ac/Gc-SLNnT), Ac/Gc sialyl-
Lewis X (Ac/Gc-SLeX) and Ac/Gc monosialylated ganglioside 1
(Ac/Gc-GM1) (Table 1; Fig. S2). SubB2M and the anti-Neu5Gc IgY did
not bind to any of the Neu5Ac structures, while wild-type SubB
recognised the Ac-SLNnT with a KD of 2.68 mM (Table 1). Wild-type
SubB bound Gc-SLeX with a similar KD (2.06 mM; Table 1) to the
recognition of Ac-SLNnT and the addition of the branched fucose to
the Gc-SLNnT (Gc-SLeX) reduced the KD by 300-fold. SubB2M
bound Gc-SLeXwith a KD (94.85nM), 21.7-fold better than thewild-
type SubB but still 31-fold reduced afﬁnity compared to the non-
fucosylated Gc-SLNnT (Table 1). The anti-Neu5Gc IgY did not bind
to Gc-SLeX at a maximum concentration of 20 mM (Table 1). The Gc-
GM1 was bound by all three proteins with 20e100 fold less afﬁnity
than the Gc-SLNnT demonstrating that all three of these proteins
prefers Neu5Gc presented as the terminal sugar (exo) rather than
on a internal branch (endo).
Fig. 1. SubBWT and 2M analysis with Z-biotech Neu5Ac/Gc arrays. (A.) Glycan array images. Region 1 (Top and 3 spots at bottom right of each subarray)¼Neu5Gc Glycans. Region
2 (Bottom of each subarray)¼Neu5Ac glycans. Region 3 (Right side of each subarray)¼ Control spots. (B.) Glycan array relative ﬂuorescent units (RFU, above background ﬂuo-
rescence) of wild-type SubB protein and (C.) SubB2M protein. Neu5Gc glycans are shown in blue, Neu5Ac glycans are shown in red. For full list of glycans on the array see Fig. S1. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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To conﬁrm the speciﬁcity of SubB2M for Neu5Gc containing
glycoproteins, a set of puriﬁed glycoproteins from human and
bovine sources were analysed by far-western blotting. Bovine
sources were selected as previous publications have demonstrated
that bovine serum glycoproteins present a mixture of Neu5Ac andNeu5Gc sialylglycoconjugates [9,13], which are likely to be repre-
sentative of human cancer antigens [3]. In our previous study, the
human AGP was found to contain less than 1% Neu5Gc, while the
bovine AGP contained a roughly 50% mixture of Neu5Gc and
Neu5Ac, as determined by mass spectrometric analysis [9]. Fetuin,
asialofetuin and puriﬁed MUC1 from bovine sources were also
included in this analysis. While the high molecular weight of
Table 1
SPR analysis of Neu5Ac/Neu5Gc pairs.
Structure Terminal SubB WT SubB2M NeuGc-IgY
Ac-SLeX NCDI NCDI NCDI
Gc-SLeX 2.058 mM± 0.74 94.85 nM± 6.6 NCDI
Ac-SLNnT 2.684 mM± 1.4 NCDI NCDI
Gc-SLNnT 6.78 nM± 4.7 3.07 nM± 0.58 164.4 nM± 110
Ac-GM1 NCDI NCDI NCDI
Gc-GM1 606.2 nM± 104 178.6 nM± 24.3 3.482 mM± 1.03
NCDI: No concentration dependent interaction with glycan up to 20 mM in concentration.
Fig. 2. Far-western blot analyses of puriﬁed and serum glycoproteins from human
and bovine sources. Puriﬁed serum glycoproteins (hAGP ¼ human a1-acid glycoprotein,
bAGP ¼ bovine a1-acid glycoprotein, F ¼ bovine fetuin, aF ¼ bovine asialofetuin,
MUC1 ¼ bovine MUC1) as well as normal human serum (H) and bovine serum (B) were
treated with (þ) or without () a2-3,6,8,9 neuraminidase to remove all sialic acids from
glycoproteins. Membranes were probed with wild-type SubB, SubB2M, anti-Neu5Gc IgY
antibody or SNA-1. Complete far-western blot images including controls and Coomassie
stained gels can be found in Supplementary Material (Fig. S3 and Fig. S4).
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ciently resolving in SDS-PAGE, some smaller molecular weight
glycoforms were resolved.
SubB2M had a clear preference for glycoproteins from the
bovine sources compared to human and showed greater binding
thanwild-type SubB (Fig. 2). This binding was sialic acid dependent
as binding was abolished upon treatment of the glycoproteins with
an a2-3,6,8,9 neuraminidase. A minimal amount of binding was
observed to the human AGP by SubB2M. This was likely due to the
small amount of Neu5Gc present on this glycoprotein that was able
to be detected by SubB2M only. There was also a small amount of
reactivity with the asialofetuin, which was lost upon treatment
with a broad range neuraminidase suggesting that there was
incomplete desialylation of this protein (Fig. 2).
Positive controls performed with the anti-Neu5Gc IgY antibody
veriﬁed the presence of Neu5Gc on the analysed glycoproteins,
with binding of this antibody only observed to glycoproteins from
the bovine sources (Fig. 2). The lectin SNA-1, which binds prefer-
entially to a2-6 linked sialic acids, and to a lesser degree, a2-3
linked sialic acids, was also used to verify the presence of sialic
acids on glycoproteins and the loss of sialic acid following neur-
aminidase treatment (Fig. 2). This lectin had weaker binding to the
human and bovine AGP suggesting that the predominant sialic acid
linkage on these glycoproteins is a2-3 linked Neu5Ac/Gc.
To further verify the speciﬁcity of SubB2M, this mutant protein
was used to probe normal human serum and bovine serum, also by
far-western blot analysis. As humans cannot produce Neu5Gc due
to the lack of an active CMAH enzyme but can acquire Neu5Gc from
dietary sources, normal human sera should have lower amounts of
Neu5Gc glycoconjugates compared to bovine serum [7]. Both the
wild-type SubB and SubB2M showed a preference for binding to
glycoproteins from the bovine serum, with less binding observed
for the human serum glycoproteins (Fig. 2). The binding to the
human serum is likely due to the small amounts of Neu5Gc gly-
coconjugates present in this sample. Again the SubB2M showed
stronger reactivity with the bovine serum glycoproteins compared
to the wild-type version indicating a higher afﬁnity for Neu5Gc
containing structures. The binding by SubB and SubB2M was
conﬁrmed to be Neu5Gc dependent by treatment of serum samples
with neuraminidase. This resulted in loss of binding by both SubB
proteins (Fig. 2).
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with bovine serum without neuraminidase treatment conﬁrming
the presence of Neu5Gc glycoconjugates in this sample. SubB2M
showed greater reactivity to Neu5Gc-containing glycoproteins
compared to the antibody (Fig. 2).
3.3. SPR analysis of Neu5Gc-glycoproteins spiked into human
serum
To determine if the SubB2M protein is capable of detecting
Neu5Gc containing glycoproteins in human serum, bovine AGP and
native bovine MUC1 were spiked into normal human serum. The
bovine AGP used has been previously examined using glyco-
proteomics [9] and was found to only have one Neu5Gc glycosyl-
ation on the protein, so initially the bovine AGP was used at a
maximum concentration of 1mM, equivalent to 1mM of Neu5Gc
containing glycan. The wild-type SubB interacted strongly with the
NHS control and so interactions with the bovine AGP when present
were less than the background (Fig. 3A). SubB2Mwas able to detect
down to 62.5nM of bovine AGP above background (Fig. 3B). NoFig. 3. SPR analysis of SubBWT, 2M and anti-Neu5Gc IgY with spiked normal human seru
protein, (B.) SubB2M protein and (C.) anti-Neu5Gc IgY. NHS spiked with bovine MUC1 (bM
Multiple cycle analysis of the binding of spiked serum above NHS serum background. Each l
binding values above zero.binding was observed at any of these concentrations of bovine AGP
tested using the anti-Neu5Gc antibody (Fig. 3C). Using these data as
a guide, native bovine MUC1 was initially analysed at a maximum
concentration of 200nM down to 1.5625nM across a 2-fold dilution
series. This was recalibrated based on the results with SubB and
SubB2M analysed and was started at 1nM (Fig. 3D and E), while the
200nM data was used for the anti-Neu5Gc IgY (Fig. 3F). SubB2M
showed the same response to 0.125nM of bovine MUC1 above NHS
background as wild-type SubB showed to 1nM and anti-Neu5Gc
IgY to 200nM.
4. Discussion
Detection of Neu5Gc in human serum and other bodily ﬂuids
could be utilised as a diagnostic and prognostic marker in a range of
human cancers including breast, ovarian, prostate, colon and lung
cancer [5,6]. The SubB2M mutant was previously shown to have
improved recognition of Neu5Gc compared to both wild-type SubB
and the anti-Neu5Gc IgY antibody produced by Sialix (now sup-
plied by Biolegend) but this was limited to a small subset ofm (NHS). NHS spiked with bovine a1-acid glycoprotein (AGP) with (A.) wild-type SubB
UC1) with (D.) wild-type SubB protein, (E.) SubB2M protein and (F.) anti-Neu5Gc IgY.
ine represents one concentration of protein in 1% NHS. Interactions are represented by
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study we used a comprehensive Neu5Ac/Gc glycan array to
examine the full range of SubB2M binding. These studies demon-
strated that SubB2M recognises Neu5Gc glycans exclusively, with
only very low signals for a small number of Neu5Ac containing
glycans. Compared to the SubB wild-type protein this represents a
4e5 fold improvement in selectivity and speciﬁcity. Importantly,
SubB2M had improved recognition of the fucosylated Neu5Gc
containing glycans, sialyl-Lewis A and X. These glycans have great
potential to be cancer biomarkers [10]. The Neu5Ac/Gc array anal-
ysis demonstrated that the wild-type SubB protein did not recog-
nise Neu5Gc very well when a sub-terminal fucose was present
(Glycans 6, 9, 14, 17, 20, 23, 29 and 35; Fig. 1B and C, Fig. S1). The
deﬁciency was overcome in the SubB2M protein and was not pre-
viously noted in our prior studies [1,9]. The SPR analysis also
demonstrated that the anti-Neu5Gc IgY was not able to recognise
sialyl-Lewis X at concentrations below 20 mM (Table 1; Fig. S2)
indicating that SubB2M is also an improvement over the anti-
Neu5Gc antibody when it comes to recognising Neu5Gc Lewis
antigens.
Puriﬁed glycoproteins and serum glycoproteins from bovine
sources were used in this study to represent glycoproteins enriched
in Neu5Gc, and therefore to mimic the aberrant Neu5Gc glycosyl-
ation potentially present in human cancer serum samples. Far-
western blot analysis clearly demonstrated that SubB2M had a
preference for binding to glycoproteins from bovine sources, with
stronger reactivity compared to the wild-type version, further
demonstrating the utility of SubB2M as a cancer diagnostic tool and
as a Neu5Gc speciﬁc lectin.
SPR was then used to determine if the SubB2M protein could
detect elevated levels of Neu5Gc containing glycoproteins within
normal human serum. The SubB2M protein was found to be able to
detect 62.5nM bovine AGP spiked into NHS. This is equivalent to
62.5nM of Neu5Gc glycan due to there only being one Neu5Gc
glycan per protein [9] or 6.25mM of Neu5Gc in 100% serum. The
wild-type SubB and the anti-Neu5Gc IgY were unable to detect any
amount of bovine AGP above the serum control at 1mM (100mM
100% serum equivalent) suggesting that the SubB2M protein is a
signiﬁcant improvement for a potential diagnostic over the wild-
type protein and the IgY antibody.
A known human cancer serum biomarker is the heavily gly-
cosylated mucin, MUC1 [15e17]. Levels of MUC1 are elevated in
many kinds of epithelial tumors and tumor associated MUC1 has
shortened glycosylation with extensive sialylation [18,19]. The
presence of Neu5Gc has been conﬁrmed on this human tumor
antigen [20]. We used bovine MUC1, which is sialylated with both
Neu5Gc and Neu5Ac, to mimic human tumor associated MUC1.
The presence of Neu5Gc on bovine MUC1 was conﬁrmed in our
far-western blot analysis. When bovine MUC1 was spiked into
NHS a much better signal to noise ratio was obtained for all three
proteins; SubB2M, wild-type SubB and the anti-Neu5Gc IgY.
SubB2M showed the best response to bovine MUC1 and detection
at concentrations of <1nM.
SubB2M was previously found to have improved speciﬁcity and
selectivity compared to the anti-Neu5Gc IgYantibody and the wild-
type SubB protein [9]. Here we have provided further evidence that
SubB2M offers a signiﬁcant improvement over both wild-type SubB
and the anti-Neu5Gc antibodywith increased binding to differently
linked Neu5Gc, and Neu5Gc on a wide range of structures,
including fucosylated Lewis antigens, and on various serum gly-
coproteins. These outcomes suggest that SubB2M will be a useful
tool for the testing of serum and other bodily ﬂuids for the diag-
nosis and determining the prognosis of individuals with cancer or
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